Introduction
============

COPD is a leading cause of morbidity and mortality throughout the world and creates an enormous social and economic burden on the entire population.[@b1-copd-13-1675] The overall impact of COPD on individuals is multifaceted and it causes impairment not only in the lungs but also in other organs, and even in psychological conditions, which result in multiple symptomatic effects and poorer quality of life. Therefore, the Global Initiative of Chronic Obstructive Lung Disease (GOLD) proposed a novel multidimensional assessment since 2011 that included the level of health status and the risk of experiencing an exacerbation in addition to lung function.[@b1-copd-13-1675]

Both the COPD Assessment Test (CAT) and the Clinical COPD Questionnaire (CCQ) were recommended as comprehensive symptom measures by the GOLD.[@b2-copd-13-1675] The CAT was developed by Jones et al[@b3-copd-13-1675] in 2009 and consists of 8 items related to respiratory disorders: cough, phlegm, chest tightness, breathlessness, activity limitation at home, confidence in leaving home, sleep, and energy. The CCQ was developed and validated in 2003 and has 3 domains (symptoms, mental, and functional), with items scored from 0 to 6.[@b4-copd-13-1675] The CAT and CCQ have some common features: both of these 2 tools contain items of cough, phlegm, and breathlessness; in addition, higher scores correspond with a worse health status. However, the tools also differ in some details: compared with the CAT, the CCQ has a more detailed assessment of physical and mental activities whereas it does not focus on the patient's chest tightness and sleep quality. Moreover, the cutoff for the CCQ is still controversial: GOLD 2013 suggested a cutoff point of \>1 for the CCQ 2; however, Kon et al[@b5-copd-13-1675] found that 1.5 may be a more appropriate cutoff point for classifying symptom levels.

To the best of our knowledge, there have been no studies focused on the utility of the CCQ in a clinical population from mainland China. The main objective of this work was to compare the evaluation of symptom severity between the CAT and the CCQ and to find a cutoff value of the CCQ for the Chinese clinical population. In addition, we also examined the correlation between the CAT, the CCQ, the modified Medical Research Council (mMRC) questionnaire, lung function, and exacerbation history.

Methods
=======

Study design and subjects
-------------------------

This was an observational, cross-sectional, cohort study that aimed to compare the CAT and CCQ in outpatients with stable COPD from the Second Xiangya Hospital of Central South University (registration number: ChiCTR-OOC-15007352). All participants in the study provided a written informed consent. The study was approved by the Second Xiangya Hospital of Central South University institutional review board (Hunan, China).

Patients diagnosed with stable COPD in the outpatient department were enrolled from November 2015 to December 2016. All patients were aged \>40 years. Patients were also required to have the ability to undertake spirometry with a ratio of the forced expiratory volume in 1 s to the forced vital capacity (FEV~1~/FVC) lower than 0.70 after bronchodilation.[@b2-copd-13-1675] Patients who refused to complete questionnaires and those with asthma, lung cancer or other lung disease under active treatment, such as tuberculosis or pneumonia, were excluded.

Data collection and definition of exacerbation history
------------------------------------------------------

Information on age, sex, smoking status, number of exacerbations in the previous year, height, weight, lung function, and the scores of the mMRC, CAT, and CCQ were recorded. Exacerbations in the previous year were assessed according to event-based definition: worsening or new onset of any respiratory symptoms (cough, sputum volume or purulence, wheezing, or dyspnea) for at least 3 days that leads to any 1 of following situations: 1) requiring prescription change: increase in the dose or/and frequency of bronchodilator at home or requiring treatment with oral corticosteroids or/and antibiotics under the guidance of a physician in the outpatient department; 2) requiring a hospitalization and diagnosed with acute exacerbations of COPD (AECOPD); and 3) requiring an emergency room visit and diagnosed with AECOPD.

### mMRC

The mMRC dyspnea scale is used for grading the effect of breathlessness (dyspnea) on daily activities. Patients select 1 of 5 grades that most closely corresponds to their level of impairment, from grade 0 (least severe breathlessness) to grade 4 (most severe breathlessness).

CAT
---

The CAT consists of 8 items, with scores ranging from 0 to 5 (0 = no impairment, 5 = greatest impairment). An overall score is calculated by simply adding the points of the 8 questions ranging from 0 to 40, with higher scores indicating more severe health status impairment or a poorer control of COPD. Four scores of 0--10, 11--20, 21--30, and 31--40 represent low, medium, high, and very high impact level, respectively.[@b6-copd-13-1675]

CCQ
---

The CCQ contains 10 items, divided into 3 domains (symptoms, functional, and mental state). The total score is calculated by adding all answers and dividing them by the number of questions, that is, by 10. Similarly, domains are calculated by adding each domain's answers and dividing by 4 for the symptom and the functional domain and by 2 for the mental domain.[@b4-copd-13-1675] The CCQ results can be interpreted as: acceptable (CCQ\<1); acceptable for moderate disease (1≤CCQ\<2); instable-severe limited (2≤CCQ\<3); and very instable-very severe limited (CCQ≥3).[@b6-copd-13-1675]

Statistical analysis
--------------------

All data were input and analyzed using SPSS 20.0 software. The chi-square, analysis of variance, and Mann--Whitney *U*-test were used as appropriate to compare differences between groups. Kappa coefficient was used to analyze the agreement between the CAT and the CCQ. The kappa value was based on the literature, in which *k*\<0.00 is "poor," 0\<*k*\<0.02 is "slight," 0.21\<*k*\<0.40 is "fair," 0.41\<*k*\<0.60 is "moderate," 0.61\<*k*\<0.80 is "substantial," 0.81\<*k*\<1.00 is "almost perfect," and *k*=1 is "perfect" agreement.[@b7-copd-13-1675] The correlation between health status questionnaires (CAT and CCQ), lung function, and exacerbation frequency in the previous year and the mMRC dyspnea scale was calculated by the Spearman rank correlation coefficient (rho). Differences were considered statistically significant when *P*\<0.05.

Results
=======

Study population
----------------

A total of 372 patients diagnosed with COPD from the outpatient department completed all the 3 symptom-evaluation questionnaires (mMRC, CAT, and CCQ) and met the inclusion criteria. Basic characteristics of participants are shown in [Table 1](#t1-copd-13-1675){ref-type="table"}. The majority of patients were male, with an average age of 62.2 years. The mean body mass index was 22.3 kg/m^2^. More than half of the subjects had experienced at least 1 exacerbation in the last 12 months, and a quarter of them had 2 or more. The mean FEV~1~% predicted was 48.6. Based on the GOLD 2007 classification, 8.1% patients had mild COPD (grade 1), 32.8% moderate COPD (grade 2), 46.2% had severe COPD (grade 3), and 12.9% had very severe COPD (grade 4). The mean (SD) scores of the mMRC, CAT, and CCQ were 1.9 (0.9), 15.4 (6.0), and 2.0 (0.7), respectively.

Differences in the assessment of health status between CCQ and CAT
------------------------------------------------------------------

According to the CAT, only 20.4% of patients belonged to the high (21≤CAT≤30) and very high (31≤CAT≤40) impact levels, which were statistically lower than those of the CCQ, which classified over half of the population (51.1%) into the instable-severe limited (2≤CCQ\<3) and very instable-very severe limited (CCQ≥3) categories correspondingly (*P*\<0.001, data not shown).

The CCQ cutoff point of 1.0 classified 97.3% of patients into the high symptom group (groups B and D), which was statistically higher than that of the CAT (82.3%) and CCQ with a cutoff point of 1.5 (78.0%). No significant difference was observed in the proportion of subjects who had more symptoms between the CAT and CCQ with the cutoff point of 1.5 ([Figure 1](#f1-copd-13-1675){ref-type="fig"}). The kappa of agreement for the symptom groups by CAT and CCQ (cutoff point 1.5) was 0.495, suggesting moderate agreement ([Table 2](#t2-copd-13-1675){ref-type="table"}), but slight agreement (0.144) was found between the CAT and CCQ with the cutoff point of 1.0 ([Table 3](#t3-copd-13-1675){ref-type="table"}).

FEV~1~/FVC, FEV~1~% predicted, exacerbation frequency, and mMRC in different CAT and CCQ categories
---------------------------------------------------------------------------------------------------

Because there were only 4 patients in the very high (31≤CAT≤40) group of CAT, we compared only lung function, exacerbation frequency, and mMRC between mild, high, and very high CAT categories. As shown in [Tables 4](#t4-copd-13-1675){ref-type="table"} and [5](#t5-copd-13-1675){ref-type="table"}, with higher impact levels of the CAT or increased severity of the CCQ, both exacerbation frequency and the mMRC score were markedly increased (*P*\<0.001), whereas FEV~1~/FVC and FEV~1~% predicted significantly decreased (*P*\<0.001). However, no statistical differences were found in FEV~1~/FVC and FEV~1~% predicted between patients in the acceptable (CCQ\<1) and acceptable for moderate disease (1≤CCQ\<2) groups (*P*\>0.05). Moreover, subjects from the instable-severe limited and very instable-very severe limited group by the CCQ also had no difference in FEV~1~/FVC (*P*\>0.05).

Score of CAT and CCQ in different GOLD grades
---------------------------------------------

Both the CAT and the CCQ total score increased with the COPD severity assessed by GOLD grades ([Table 6](#t6-copd-13-1675){ref-type="table"}). The total CAT and CCQ scores were significantly higher in subjects from grade 2 vs 3 and those from grade 3 vs 4; however, no statistical differences were observed between grades 1 and 2. We also compared the 3 domains of the CCQ among all GOLD grades. Participants classified as grades 1, 2, and 3 had no statistically different scores in the CCQ symptom and mental domain, but patients in grades 3--4 scored significantly higher than those from grades 1--2 in the CCQ functional domain. Fewer exacerbations in the last 12 months were reported among patients in grade 1 compared with grades 3--4 (*P*\<0.05), whereas there was no statistical difference in the number of exacerbations between grades 1--2, grades 2--3, and grades 3--4 ([Table 6](#t6-copd-13-1675){ref-type="table"}).

Score of CAT and CCQ by exacerbation frequencies in the previous year
---------------------------------------------------------------------

According to exacerbation frequencies, we classified patients into 3 levels: 0 exacerbation, 1 exacerbation, and 2 or more exacerbations. Of 372 subjects, 175 (47%) had no exacerbations in the last year. The mean CAT score was 12.69 (5.11), and the average score of total CCQ, symptom domain, functional domain and mental domain were 1.70 (0.60), 1.84 (0.68), 1.60 (0.69), and 1.41 (1.09), respectively. All the results of health status questionnaires of patients with no exacerbations were significantly lower than those of participants who had 1 exacerbation. A similar trend was also observed between patients who reported 1 exacerbation and those had at least 2 exacerbations in the last 12 months; however, there was no statistical difference in FEV~1~% predicted between these 2 groups, despite the fact that subjects who never had exacerbations had a statistically higher value of FEV~1~% predicted than those who reported at least 1 exacerbation ([Table 7](#t7-copd-13-1675){ref-type="table"}).

Distribution of CAT and CCQ levels into different exacerbation frequencies
--------------------------------------------------------------------------

[Figures 2](#f2-copd-13-1675){ref-type="fig"} and [3](#f3-copd-13-1675){ref-type="fig"} show the distribution of CAT and CCQ levels into different exacerbation frequencies. With the higher level of CAT and CCQ (worse health status), the proportion of participants who had no exacerbations in the previous year gradually decreased, but the percentage of subjects who reported at least 2 exacerbations had a completely opposite trend.

Among the subjects with frequent exacerbations (≥2), only 2.2% had a CAT score \<10 (fewer symptoms), and 5.4% had a total CCQ score \<1.5. In addition, no patient had a score of total CCQ \<1.0 (data not shown).

Spearman rank correlations between CAT and CCQ questionnaires, lung function, exacerbation frequency, and mMRC dyspnea scale
----------------------------------------------------------------------------------------------------------------------------

In comparing FEV~1~% predicted results, the mMRC and all 3 domains of the CCQ, the CAT, and the total CCQ score had a much better correlation with exacerbation frequency ([Table 8](#t8-copd-13-1675){ref-type="table"}). Moreover, the CAT and the total CCQ were significantly correlated with each other (rho=0.776, *P*\<0.01). The CCQ 1.0 and 1.5 corresponded to CAT 4.2 and 9.7, respectively. The CAT 10.0 was equivalent to 1.53 of the CCQ ([Figure 4](#f4-copd-13-1675){ref-type="fig"}).

Discussion
==========

The main findings of this cross-sectional study were as follows: 1) compared with the CAT, the CCQ was more likely to classify the patients into more severe categories, and it seemed that 1.5 rather than 1.0 might be a better cutoff point for the CCQ and 2) both the CAT and the overall CCQ with its 3 domains could discriminate between groups of patients who differ in COPD severity.

The CAT and CCQ results can be categorized into 4 levels: scores of 0--10, 11--20, 21--30, and 31--40 represent low, medium, high, and very high impact level by CAT. Correspondingly, scores of the CCQ can be considered as acceptable (CCQ\<1), acceptable for moderate disease (1≤CCQ\<2), instable-severe limited (2≤CCQ\<3), and very instable-very severe limited (CCQ≥3).[@b6-copd-13-1675] In this study, 51.1% of patients had instable-severe limited or very instable-very severe limited disease (CCQ≥2), whereas only 20.5% were in the high-very high group of CAT (CAT≥21), which had a statistical difference. This could be explained by the most obvious difference between these 2 instruments, which is that CAT has no corresponding items related to the mental domain of the CCQ. We further observed that 120 subjects who had a score of CCQ≥2 were classified into mild-medium impact levels by CAT (CAT\<20), importantly, all 120 subjects had mental impairment, with an average score of (2.3±0.9) in the mental domain. Evidence has shown that mental diseases, such as depression and anxiety in COPD patients can have significantly deleterious effects, including an increased length of hospitalization and mortality risk.[@b8-copd-13-1675]--[@b10-copd-13-1675] Our work also confirmed that patients with more exacerbations had worse mental status; thus, the management and treatment of mental disease in COPD should be paid much more attention.

A notable finding of this study is that 1.5 is a more appropriate cutoff point for the CCQ than 1.0, at least in the Chinese population. We show that for the CCQ 1.0 and 1.5, CAT is equivalent to 4.2 and 9.7, respectively, and the CAT score of 10.0 corresponds with a score of 1.53 on the CCQ. These results are consistent with Kon's study[@b5-copd-13-1675] Our work also finds that when the cutoff value of the CCQ is 1.5, it has a better agreement with the CAT than that of 1.0 in the classification of symptom groups, which again confirms that 1.5 is a better cutoff point for the CCQ.

Our study demonstrated that the CAT and CCQ correlated well with each other and both were able to clearly distinguish between patients with different COPD severity assessed by exacerbation rates, FEV~1~% predicted, and mMRC. With higher scores of the CAT and CCQ, subjects displayed more impairment in lung function, higher level of mMRC, and greater number exacerbations in the last year. Similarly, patients with more exacerbations presented worse scores on the CAT and total CCQ as well as its 3 domains, which suggested that the CAT and CCQ might be good indicators of exacerbation frequencies. Other studies also support our findings: both these health status questionnaires have proved to be associated with exacerbations,[@b11-copd-13-1675] and CAT has been identified as a strong predictor of the composite events in COPD.[@b12-copd-13-1675]--[@b15-copd-13-1675] Miravitlles et al[@b16-copd-13-1675] found that scores of both the CAT and CCQ significantly decreased when subjects recovered from exacerbations. However, in our study no obvious differences were detected in the score of the CAT, and the total CCQ as well as its 3 domains between grades 1 and 2. In addition, only weak correlation was obtained between the 2 tools and FEV~1~% predicted. These results were in keeping with Jones[@b17-copd-13-1675] and Josephs[@b18-copd-13-1675] studies. We also found that both the CAT and CCQ had a much stronger correlation with the number of exacerbations in the last 12 months than FEV~1~% predicted. COPD is a heterogeneous disease with different clinical phenotypes both in the stable phase and in acute exacerbations,[@b19-copd-13-1675],[@b20-copd-13-1675] and a variety of risk factors are associated with exacerbations.[@b21-copd-13-1675],[@b22-copd-13-1675] Therefore, prediction of FEV~1~% alone cannot accurately reflect the full impact of COPD on daily life.

Limitations to this study include the following: first, this study was limited to 1 single center; second, this was a cross-sectional study without any analysis of prospective data on exacerbations. A further study should focus on a comparison of predictive value of the CAT, CCQ, FEV~1~% predicted, and exacerbation history for the future exacerbations in COPD.

Conclusion
==========

As comprehensive health status measures, both the CAT and the CCQ were proposed by GOLD. In comparison with the CAT, the CCQ was more likely to place patients into more severe categories, and 1.5 is a more appropriate cutoff point for the CCQ than 1.0. Both the CAT and the overall CCQ with its 3 domains could clearly discriminate between patients with different COPD severity.
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###### 

Demographic and clinical characteristics of participants with COPD

  Characteristics                               All patients (n=372)
  --------------------------------------------- ----------------------
  Age (years)                                   62.2±8.3
  Gender                                        
   Male                                         319 (85.8%)
   Female                                       53 (14.2%)
  BMI (kg/m^2^)                                 22.3±3.5
  Smoking pack years                            40.0±32.2
  Exacerbations in the last 12 months           
   0                                            175 (47.0%)
   1                                            104 (28.0%)
   ≥2                                           93 (25.0%)
  FEV~1~/FVC                                    0.44±0.13
  FEV~1~% predicted                             48.6±18.9
  mMRC                                          1.9±0.9
  CAT                                           15.4±6.0
   Mild (0--10)                                 85 (22.8%)
   Medium (11--20)                              211 (56.7%)
   High (21--30)                                72 (19.4%)
   Very high (31--40)                           4 (1.1%)
  CCQ                                           2.0±0.7
   Acceptable (CCQ\<1)                          10 (2.7%)
   Acceptable for moderate disease (1≤CCQ\<2)   172 (46.2%)
   Instable-severe limited (2≤CCQ\<3)           156 (41.9%)
   Very instable-very severe limited (CCQ≥3)    34 (9.2%)
  GOLD grades                                   
   1: Mild                                      30 (8.1%)
   2: Moderate                                  122 (32.8%)
   3: Severe                                    172 (46.2%)
   4: Very severe                               48 (12.9%)

**Note:** Data presented as mean ± SD or n (%).

**Abbreviations:** BMI, body mass index; CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, global initiative for chronic obstructive lung disease; mMRC, modified Medical Research Council dyspnea score.

###### 

Kappa of agreement for the symptom groups by CAT and CCQ (cutpoint =1.5)

  CCQ cutpoint =1.5   CAT         
  ------------------- ----- ----- -----
  Groups A and C      44    38    82
  Groups B and D      22    268   290
  Total               66    306   372

**Note:** Kappa=0.495, moderate agreement.

**Abbreviations:** CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire.

###### 

Kappa of agreement for the symptom groups by CAT and CCQ (cutpoint =1.0)

  CCQ cutpoint =1.0   CAT         
  ------------------- ----- ----- -----
  Groups A and C      7     3     10
  Groups B and D      59    303   362
  Total               66    306   372

**Note:** Kappa=0.144, slight agreement.

**Abbreviations:** CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire.

###### 

FEV~1~/FVC, FEV~1~% predicted, exacerbation frequency and mMRC in different CAT categories

  Variables                                 Mild 0≤CAT≤10                                                                                           Medium 11≤CAT≤20                                                                                        High 21≤CAT≤30                                                                                           *P*-value
  ----------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -----------
  FEV~1~/FVC                                0.47±0.13[\#](#tfn8-copd-13-1675){ref-type="table-fn"},[▲](#tfn9-copd-13-1675){ref-type="table-fn"}     0.44±0.12[\*](#tfn7-copd-13-1675){ref-type="table-fn"},[▲](#tfn9-copd-13-1675){ref-type="table-fn"}     0.39±0.14[\*](#tfn7-copd-13-1675){ref-type="table-fn"},[\#](#tfn8-copd-13-1675){ref-type="table-fn"}     \<0.001
  FEV~1~ % predicted                        54.73±20.91[\#](#tfn8-copd-13-1675){ref-type="table-fn"},[▲](#tfn9-copd-13-1675){ref-type="table-fn"}   48.28±17.48[\*](#tfn7-copd-13-1675){ref-type="table-fn"},[▲](#tfn9-copd-13-1675){ref-type="table-fn"}   42.72±18.79[\*](#tfn7-copd-13-1675){ref-type="table-fn"},[\#](#tfn8-copd-13-1675){ref-type="table-fn"}   \<0.001
  Exacerbation frequency in the last year   0.28±0.59[\#](#tfn8-copd-13-1675){ref-type="table-fn"},[▲](#tfn9-copd-13-1675){ref-type="table-fn"}     0.92±1.22[\*](#tfn7-copd-13-1675){ref-type="table-fn"},[▲](#tfn9-copd-13-1675){ref-type="table-fn"}     1.86±1.37[\*](#tfn7-copd-13-1675){ref-type="table-fn"},[\#](#tfn8-copd-13-1675){ref-type="table-fn"}     \<0.001
  mMRC                                      1.18±0.69[\#](#tfn8-copd-13-1675){ref-type="table-fn"},[▲](#tfn9-copd-13-1675){ref-type="table-fn"}     1.79±0.83[\*](#tfn7-copd-13-1675){ref-type="table-fn"},[▲](#tfn9-copd-13-1675){ref-type="table-fn"}     2.50±0.71[\*](#tfn7-copd-13-1675){ref-type="table-fn"},[\#](#tfn8-copd-13-1675){ref-type="table-fn"}     \<0.001

**Notes:**

*P*\<0.05 vs 0≤CAT≤10;

*P*\<0.05 vs 11≤CAT≤20;

*P*\<0.05 vs 21≤CAT≤30.

**Abbreviations:** CAT, COPD Assessment Test; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; mMRC, modified Medical Research Council.

###### 

FEV~1~/FVC, FEV~1~% predicted, exacerbation frequency, and mMRC in different CCQ categories

  Variables                                 Acceptable CCQ\<1                                                                                                                                     Acceptable for moderate disease 1≤CCQ\<2                                                                                                              Instable-severe limited 2≤CCQ\<3                                                                                                                         Very instable-very severe limited CCQ≥3                                                                                                                  *P*-value
  ----------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  FEV~1~/FVC                                59.90±15.82[▲](#tfn13-copd-13-1675){ref-type="table-fn"},[¶](#tfn14-copd-13-1675){ref-type="table-fn"}                                                46.19±12.11[▲](#tfn13-copd-13-1675){ref-type="table-fn"},[¶](#tfn14-copd-13-1675){ref-type="table-fn"}                                                42.05±12.33[\*](#tfn11-copd-13-1675){ref-type="table-fn"},[\#](#tfn12-copd-13-1675){ref-type="table-fn"}                                                 37.51±11.52[\*](#tfn11-copd-13-1675){ref-type="table-fn"},[\#](#tfn12-copd-13-1675){ref-type="table-fn"}                                                 \<0.001
  FEV~1~ % predicted                        62.53±21.06[▲](#tfn13-copd-13-1675){ref-type="table-fn"},[¶](#tfn14-copd-13-1675){ref-type="table-fn"}                                                51.53±18.10[▲](#tfn13-copd-13-1675){ref-type="table-fn"},[¶](#tfn14-copd-13-1675){ref-type="table-fn"}                                                46.65±18.94[\*](#tfn11-copd-13-1675){ref-type="table-fn"},[\#](#tfn12-copd-13-1675){ref-type="table-fn"},[¶](#tfn14-copd-13-1675){ref-type="table-fn"}   38.34±17.39[\*](#tfn11-copd-13-1675){ref-type="table-fn"},[\#](#tfn12-copd-13-1675){ref-type="table-fn"},[▲](#tfn13-copd-13-1675){ref-type="table-fn"}   \<0.001
  Exacerbation frequency in the last year   0.10±0.32[\#](#tfn12-copd-13-1675){ref-type="table-fn"},[▲](#tfn13-copd-13-1675){ref-type="table-fn"},[¶](#tfn14-copd-13-1675){ref-type="table-fn"}   0.49±0.98[\*](#tfn11-copd-13-1675){ref-type="table-fn"},[▲](#tfn13-copd-13-1675){ref-type="table-fn"},[¶](#tfn14-copd-13-1675){ref-type="table-fn"}   1.26±1.22[\*](#tfn11-copd-13-1675){ref-type="table-fn"},[\#](#tfn12-copd-13-1675){ref-type="table-fn"}                                                   2.44±1.48[\*](#tfn11-copd-13-1675){ref-type="table-fn"},[\#](#tfn12-copd-13-1675){ref-type="table-fn"},[▲](#tfn13-copd-13-1675){ref-type="table-fn"}     \<0.001
  mMRC                                      0.70±0.48[\#](#tfn12-copd-13-1675){ref-type="table-fn"},[▲](#tfn13-copd-13-1675){ref-type="table-fn"},[¶](#tfn14-copd-13-1675){ref-type="table-fn"}   1.54±0.79[\*](#tfn11-copd-13-1675){ref-type="table-fn"},[▲](#tfn13-copd-13-1675){ref-type="table-fn"},[¶](#tfn14-copd-13-1675){ref-type="table-fn"}   2.19±0.73[\*](#tfn11-copd-13-1675){ref-type="table-fn"},[\#](#tfn12-copd-13-1675){ref-type="table-fn"},[¶](#tfn14-copd-13-1675){ref-type="table-fn"}     2.68±0.77[\*](#tfn11-copd-13-1675){ref-type="table-fn"},[\#](#tfn12-copd-13-1675){ref-type="table-fn"},[▲](#tfn13-copd-13-1675){ref-type="table-fn"}     \<0.001

**Notes:**

*P*\<0.05 vs CCQ\<1;

*P*\<0.05 vs 1≤CCQ\<2;

*P*\<0.05 vs 2≤CCQ\<3;

*P*\<0.05 vs CCQ≥3.

**Abbreviations:** CCQ, clinical COPD questionnaire; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; mMRC, modified Medical Research Council dyspnea score.

###### 

Score of CAT and CCQ by GOLD grades

  Variables                Grade 1, n=30                                                                                          Grade 2, n=122                                                                                          Grade 3, n=172                                                                                                                                         Grade 4, n=48                                                                                                                                           *P*-value
  ------------------------ ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  CAT                      13.80±6.27[¶](#tfn19-copd-13-1675){ref-type="table-fn"}                                                13.89±5.28[▲](#tfn18-copd-13-1675){ref-type="table-fn"},[¶](#tfn19-copd-13-1675){ref-type="table-fn"}   15.56±5.61[\#](#tfn17-copd-13-1675){ref-type="table-fn"},[¶](#tfn19-copd-13-1675){ref-type="table-fn"}                                                 19.77±6.70[\*](#tfn16-copd-13-1675){ref-type="table-fn"},[\#](#tfn17-copd-13-1675){ref-type="table-fn"},[▲](#tfn18-copd-13-1675){ref-type="table-fn"}   \<0.001
  CCQ total                1.76±0.70[▲](#tfn18-copd-13-1675){ref-type="table-fn"},[¶](#tfn19-copd-13-1675){ref-type="table-fn"}   1.85±0.61[▲](#tfn18-copd-13-1675){ref-type="table-fn"},[¶](#tfn19-copd-13-1675){ref-type="table-fn"}    2.06±0.69[\*](#tfn16-copd-13-1675){ref-type="table-fn"},[\#](#tfn17-copd-13-1675){ref-type="table-fn"},[¶](#tfn19-copd-13-1675){ref-type="table-fn"}   2.51±0.93[\*](#tfn16-copd-13-1675){ref-type="table-fn"},[\#](#tfn17-copd-13-1675){ref-type="table-fn"},[▲](#tfn18-copd-13-1675){ref-type="table-fn"}    \<0.001
  CCQ symptom              2.02±0.84[¶](#tfn19-copd-13-1675){ref-type="table-fn"}                                                 2.06±0.76[¶](#tfn19-copd-13-1675){ref-type="table-fn"}                                                  2.16±0.80[¶](#tfn19-copd-13-1675){ref-type="table-fn"}                                                                                                 2.50±1.03[\*](#tfn16-copd-13-1675){ref-type="table-fn"},[\#](#tfn17-copd-13-1675){ref-type="table-fn"},[▲](#tfn18-copd-13-1675){ref-type="table-fn"}    =0.013
  CCQ function             1.53±0.81[▲](#tfn18-copd-13-1675){ref-type="table-fn"},[¶](#tfn19-copd-13-1675){ref-type="table-fn"}   1.70±0.68[▲](#tfn18-copd-13-1675){ref-type="table-fn"},[¶](#tfn19-copd-13-1675){ref-type="table-fn"}    1.97±0.76[\*](#tfn16-copd-13-1675){ref-type="table-fn"},[\#](#tfn17-copd-13-1675){ref-type="table-fn"}                                                 2.53±1.02[\*](#tfn16-copd-13-1675){ref-type="table-fn"},[\#](#tfn17-copd-13-1675){ref-type="table-fn"}[▲](#tfn18-copd-13-1675){ref-type="table-fn"}     \<0.001
  CCQ mental               1.68±1.05                                                                                              1.62±1.09[¶](#tfn19-copd-13-1675){ref-type="table-fn"}                                                  1.86±1.14                                                                                                                                              2.18±1.42[\#](#tfn17-copd-13-1675){ref-type="table-fn"}                                                                                                 =0.033
  Exacerbation frequency   0.37±0.67[▲](#tfn18-copd-13-1675){ref-type="table-fn"},[¶](#tfn19-copd-13-1675){ref-type="table-fn"}   0.79±1.20[¶](#tfn19-copd-13-1675){ref-type="table-fn"}                                                  1.06±1.31[\*](#tfn16-copd-13-1675){ref-type="table-fn"}                                                                                                1.65±1.41[\*](#tfn16-copd-13-1675){ref-type="table-fn"},[\#](#tfn17-copd-13-1675){ref-type="table-fn"}                                                  \<0.001

**Notes:**

*P*\<0.05 vs Grade 1;

*P*\<0.05 vs Grade 2;

*P*\<0.05 vs Grade 3;

*P*\<0.05 vs Grade 4.

**Abbreviations:** CAT, COPD Assessment Test; CCQ, clinical COPD questionnaire; GOLD, Global Initiative for Chronic Obstructive Lung Disease.

###### 

Score of CAT and CCQ by exacerbation frequencies

  Variables           Exacerbation frequency in the last 12 months                                                              *P*-value                                                                                                                                                                                                          
  ------------------- --------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ---------
  CAT                 12.69±5.11[\#](#tfn22-copd-13-1675){ref-type="table-fn"},[▲](#tfn23-copd-13-1675){ref-type="table-fn"}    15.61±4.76[\*](#tfn21-copd-13-1675){ref-type="table-fn"},[▲](#tfn23-copd-13-1675){ref-type="table-fn"}   20.33±5.57[\*](#tfn21-copd-13-1675){ref-type="table-fn"},[\#](#tfn22-copd-13-1675){ref-type="table-fn"}   \<0.001
  CCQ total           1.70±0.60[\#](#tfn22-copd-13-1675){ref-type="table-fn"},[▲](#tfn23-copd-13-1675){ref-type="table-fn"}     2.02±0.47[\*](#tfn21-copd-13-1675){ref-type="table-fn"},[▲](#tfn23-copd-13-1675){ref-type="table-fn"}    2.64±0.81[\*](#tfn21-copd-13-1675){ref-type="table-fn"},[\#](#tfn22-copd-13-1675){ref-type="table-fn"}    \<0.001
  CCQ symptom         1.84±0.68[\#](#tfn22-copd-13-1675){ref-type="table-fn"},[▲](#tfn23-copd-13-1675){ref-type="table-fn"}     2.13±0.64[\*](#tfn21-copd-13-1675){ref-type="table-fn"},[▲](#tfn23-copd-13-1675){ref-type="table-fn"}    2.78±0.92[\*](#tfn21-copd-13-1675){ref-type="table-fn"},[\#](#tfn22-copd-13-1675){ref-type="table-fn"}    \<0.001
  CCQ function        1.60±0.69[\#](#tfn22-copd-13-1675){ref-type="table-fn"},[▲](#tfn23-copd-13-1675){ref-type="table-fn"}     1.91±0.60[\*](#tfn21-copd-13-1675){ref-type="table-fn"},[▲](#tfn23-copd-13-1675){ref-type="table-fn"}    2.52±0.94[\*](#tfn21-copd-13-1675){ref-type="table-fn"},[\#](#tfn22-copd-13-1675){ref-type="table-fn"}    \<0.001
  CCQ mental          1.41±1.09[\#](#tfn22-copd-13-1675){ref-type="table-fn"},[▲](#tfn23-copd-13-1675){ref-type="table-fn"}     1.96±0.90[\*](#tfn21-copd-13-1675){ref-type="table-fn"},[▲](#tfn23-copd-13-1675){ref-type="table-fn"}    2.38±1.31[\*](#tfn21-copd-13-1675){ref-type="table-fn"},[\#](#tfn22-copd-13-1675){ref-type="table-fn"}    \<0.001
  FEV~1~% predicted   53.84±19.32[\#](#tfn22-copd-13-1675){ref-type="table-fn"},[▲](#tfn23-copd-13-1675){ref-type="table-fn"}   45.37±18.22[\*](#tfn21-copd-13-1675){ref-type="table-fn"}                                                42.25±16.30[\*](#tfn21-copd-13-1675){ref-type="table-fn"}                                                 \<0.001

**Notes:**

*P*\<0.05 vs AE=0;

*P*\<0.05 vs AE=1;

*P*\<0.05 vs AE≥2.

**Abbreviations:** CAT, COPD Assessment Test; CCQ, clinical COPD questionnaire; FEV~1~, forced expiratory volume in 1 second.

###### 

Spearman rank correlations between health status questionnaires (CAT and CCQ), lung function, exacerbation frequency in the previous year, and mMRC dyspnea scale at baseline (n=372)

  Variables                CAT   CCQ total                                               CCQ symptom                                             CCQ function                                            CCQ mental                                              mMRC                                                    FEV~1~% predicted                                        Exacerbation frequency
  ------------------------ ----- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  CAT                      --    0.776[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   0.590[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   0.688[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   0.409[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   0.614[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   −0.270[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   0.516[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}
  CCQ total                --    --                                                      0.734[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   0.829[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   0.628[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   0.540[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   −0.271[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   0.542[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}
  CCQ symptom              --    --                                                      --                                                      0.497[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   0.273[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   0.346[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   −0.271[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   0.439[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}
  CCQ function             --    --                                                      --                                                      --                                                      0.334[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   0.578[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   −0.321[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   0.468[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}
  CCQ mental               --    --                                                      --                                                      --                                                      --                                                      0.284[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   −0.132[\*](#tfn26-copd-13-1675){ref-type="table-fn"}     0.339[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}
  mMRC                     --    --                                                      --                                                      --                                                      --                                                      --                                                      −0.315[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}   0.342[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}
  FEV~1~% predicted        --    --                                                      --                                                      --                                                      --                                                      --                                                      --                                                       −0.280[\*\*](#tfn25-copd-13-1675){ref-type="table-fn"}
  Exacerbation frequency   --    --                                                      --                                                      --                                                      --                                                      --                                                      --                                                       --

**Notes:**

*P*\<0.01,

*P*\<0.05.

**Abbreviations:** CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; FEV~1~, forced expiratory volume in 1 second; mMRC, modified Medical Research Council dyspnea score.
